We are a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. Our second product candidate, GFH009, is a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor licensed from GenFleet Therapeutics, which we hold the exclusive rights to for further development and commercialization of the asset across all therapeutic and diagnostic uses outside of greater China. GPS and GFH009 have potential as monotherapies, or in combination with other therapies, to address a broad spectrum of hematologic malignancies and solid tumor indications.
View Top Employees from SELLAS Life Sciences Group, Inc.Website | https://sellaslifesciences.com/ |
Ticker | SLS |
Revenue | $7 million |
Employees | 23 (19 on RocketReach) |
Founded | 2012 |
Address | 7 Times Square Suite 2503, New York, New York 10036, US |
Phone | (646) 200-5278 |
Technologies |
JavaScript,
HTML,
Twitter
+18 more
(view full list)
|
Industry | Biopharma, Biotechnology, Biotechnology Research, Drug Manufacturing & Research, Pharmaceuticals, Drug Discovery, Clinical Devices, Healthcare, Health Care, Science and Engineering |
Web Rank | 5 Million |
Keywords | Sellas Life Sciences, Sellas Life Sciences Stock News, Sellas Life Sciences History, Sellas Galena, Sellas Life Science Group |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies |
Looking for a particular SELLAS Life Sciences Group, Inc. employee's phone or email?
The SELLAS Life Sciences Group, Inc. annual revenue was $7 million in 2024.
John Burns is the Senior Vice President, Chief Financial Officer of SELLAS Life Sciences Group, Inc..
19 people are employed at SELLAS Life Sciences Group, Inc..
SELLAS Life Sciences Group, Inc. is based in New York, New York.
The NAICS codes for SELLAS Life Sciences Group, Inc. are [325, 32541, 3254, 32].
The SIC codes for SELLAS Life Sciences Group, Inc. are [28, 283].